JPRN-jRCT2080221020未知3 期
A Phase 3 Multi-Center, Placebo-Controlled, Double Blind, 3-Armed Parallel Group, Comparative Study of SPM 962 4.5 and 6.75 mg/day to investigate superiority to Placebo in Patients with Restless Legs Syndrome
适应症
试验速览
- 阶段
- 3 期
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 79age old（—）
- 性别
- All
入选标准
- •1. Patients whose condition has been diagnosed as RLS by meeting all 4 of the IRLSSG/NIH criteria
- •2. Patients who meet any of the following criteria relating to RLS treatment:
- •- Patients who have never received treatment for RLS
- •- Patients who have received treatment for RLS in the past and responded to L-dopa or dopamine agonists (Response to other RLS medicines is irrelevant.)
- •3. Patients who have an IRLS total score of >= 15 at baseline
- •4. Patients who experience symptoms in the evening or during the night on at least two days a week within 14 days prior to commencement of study treatment
- •5. Patients and their partners can practice contraception at the end of follow-up observation period or by 1 week after the end of treatment
排除标准
- •1. Patients who have previously participated in a clinical trial of SPM962 and taken the investigational product (IP)
- •2. Patients with secondary RLS induced by renal impairment (uremia), iron deficiency anemia, drugs, pregnancy, etc
- •3. Patients who currently suffer, are at risk of developing, or have a history of sleep disorder such as sleep apnea syndrome, narcolepsy, and sleep attacks/sudden onset of sleep
- •4. Patients who have concomitant diseases or symptoms which may affect the symptoms of RLS, such as polyneuropathy (including diabetic neuropathy), akathisia, claudication, varicoses, muscle fasciculation, painful legs and moving toes syndrome, radiculopathy and folate deficiency
- •5. Patients who have other CNS diseases such as Parkinson's disease, dementia, progressive supranuclear paresis, multisystem atrophy, Huntington's Chorea, amyotrophic lateral sclerosis, and Alzheimer's disease
- •6. Patients who have psychiatric conditions such as confusion, hallucination, delusion, and excitation, or patients who have abnormal behavior such as delirium, obsessive compulsive disorder, and impulse control disorder at the time of the screening test or baseline examination
- •7. Patients whose SBP declines by at least 30 mmHg from supine to standing position based on the orthostatic hypotension assessment, or patients who develop orthostatic hypotension at baseline
- •8. Patients who have a history of epilepsy, convulsion, etc
- •9. Patients who have complications or a history of serious cardiac diseases or arrhythmia (eg, congestive heart failure of class 3 or 4 in the NYHA classification, second or third degree atrioventricular block, complete left bundle branch block, sick sinus syndrome, ventricular fibrillation, myocardial infarction within 12 months prior to the screening test, or a complication of angina pectoris)
- •10. Patients with arrhythmia who have been taking Class 1a antiarrhythmic drugs (eg, quinidine, procainamide) or Class 3 antiarrhythmic drugs (eg, amiodarone, sotalol)
- •11. Patients who have a serious ECG abnormality at the screening test and at the baseline examination
- •Patients who show QTc intervals exceeding 450 ms in both ECGs in the
- •screening test
- •Patients who have an average QTc interval from the two ECGs in the baseline assessment that exceeds 470 ms (for females) or 450 ms (for males)
- •12. Patients with congenital long QT syndrome
- •13. Patients whose serum potassium level is < 3.5mEq/L at the screening test
- •14. Patients whose total bilirubin is >= 3.0mg/dL, or whose AST(GOT) and ALT(GPT) are equal or more than 2.5 times the reference range of the clinical site (or >= 100IU/L) at the screening test
- •15. Patients whose BUN level is >= 30mg/dL, or whose serum creatinine level is >= 2.0mg/dL at the screening test
- •16. Patients who have a history of allergy to topical agents such as transdermal patch
- •17. Patients who are pregnant or nursing or who wish to become pregnant during the study period
- •18. Patients who habitually drink alcohol or smoke excessively
- •19. Patients who engage in evening shift work or other such shift work, or whose work or circumstances makes it difficult to maintain a regular period of sleep
- •20. Patients who engage in hazardous work such as driving a vehicle, operating machinery, or working in a high location.
- •21. Patients with autoimmune disease, chronic active hepatitis, or immune deficiency disorder
- •22. Patients who have a complication or history of malignant neoplastic disease, or received treatmen
研究者
相似试验
已完成
3 期
A phase III clinical trial for a novel herbal molecule (1% LLL-2011) developed by Lupin Li,ited which has a potential to prevent attacks of common migraine effectively.CTRI/2009/091/000776upin Limited (Research Park), 46A/47A, Nande village, Mulshi taluka Pune ? 411042, Maharashtra, India214
进行中（未招募）
1 期
A Phase III multicenter, double-blind, placebo-controlled, study evaluating the safety, and efficacy of STR001 treatment in adults with Sudden Sensorineural Hearing LossEUCTR2017-000242-22-DESTREKIN AG165
进行中（未招募）
1 期
A Phase III multicenter, double-blind, placebo-controlled, study evaluating the safety, and efficacy of STR001 treatment in adults with Sudden Sensorineural Hearing LossEUCTR2017-000242-22-CZSTREKIN AG165
进行中（未招募）
1 期
A Phase III multicenter, double-blind, placebo-controlled, study evaluating the safety, and efficacy of STR001 treatment in adults with Sudden Sensorineural Hearing LossEUCTR2017-000242-22-PLSTREKIN AG165
进行中（未招募）
1 期
A Phase 3, Multi-center, Double-blind, Placebo-controlled, Parallel-arm Trial to Determine Long-term Safety and Efficacy of Oral Tolvaptan Tablet Regimens in Adult Subjects with Autosomal Dominant Polycystic Kidney DiseaseAutosomal Dominant Polycystic Kidney Disease (ADPKD)MedDRA version: 8.1 Level: LLT Classification code 10036046 Term: Polycystic kidney, autosomal dominantEUCTR2006-002768-24-GBOtsuka Pharmaceutical Development & Commercialization, Inc.1,500